You searched for "intracameral"
Ocular manifestations of multiple sclerosis: an overview
Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS), in which there is dissemination of lesions in time (two or more clinical events) and space (multiple lesions seen on brain and spinal imaging). The pathophysiology...Globes in space: What would happen to our globes on the globe of Mars?
Many films have been made regarding life on alternative planets. With the Mars One mission approaching in 2023, there are high expectations regarding future interplanetary travel. The authors provide an ophthalmology perspective on what could happen to our eyes if...
Eye Surgery in Hot Climates (Fourth Edition)
The Fourth Edition of Eye Surgery in Hot Climates by William Dean and John Sandford-Smith has made a debut at a time when there is a surge of interest in global ophthalmology amongst novices and experts alike. Both authors have...Effect of minor trauma in eyes with previously undiagnosed angioid streaks
Angioid streaks (AS) may be associated with pseudoxanthoma elasticum (PXE), Paget’s disease, haemoglobulinopathies, Ehlers-Danlos Syndrome or abetalipoproteinaemia. Histopathology showed retinal pigment epithelium (RPE) and choriocapillaris loss, elastic fibre degeneration, calcium deposition, active choroidal neovascular membrane (CNVM) and vascular endothelial growth...Patients blinded by stem cells! How safe are they really?
Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: Patients blinded by stem cells! How safe are they really? Ever since the successful results following...
Intravitreal Ziv-Aflibercept: safety analysis
Ziv-Aflibercept (Zaltrap; Sanofi-Aventis U.S LLS, Bridgewater, NJ) was originally introduced as an intravenous formulation for metastatic colorectal cancer. The adoption of Ziv-Aflibercept in ophthalmic practice was similar to bevacizumab, and reports have previously examined one to two year visual outcomes...
G-CSF intravitreal injections for NAION: a pilot study
In rodent models with anterior ischemic optic neuropathy (AION), granulocyte colony-stimulating factor (G-CSF) confers a neuroprotective effect on retinal ganglion cells (RGCs) via anti-apoptotic and anti-inflammatory processes. This prospective study investigated the efficacy of intravitreal injection of G-CSF for the...
ROP ocular outcomes after Bevacizumab treatment
The relationship between refractive outcomes and biometric parameters were evaluated following intravitreal Bevacizumab (IVB) monotherapy. Sixty-three infants were grouped into 1) infants treated with VB monotherapy for ROP (six with zone 1 and eight with posterior zone II retinopathy of...
Combined ranibizumab and ablative therapy for Coat’s disease
The aim of this study was to observe the efficacy of intravitreal ranibizumab (IVR) combined with laser photocoagulation or cryotherapy, for Coats’ disease. Patients younger than 16 years of age who were diagnosed with Coats’ disease were included in this...
Short-term effects of intravitreal bevacizumab on the cornea
Bevacizumab has been extensively used to treat macula oedema and neovascularisation of the retina and it has also been useful in the management of corneal neovascular diseases. This prospective study aimed to provide more information on the effect bevacizumab may...
Effect of single intravitreal injection of bevacizumab on contrast sensitivity in patients with central retinal vein occlusion
Central retinal vein occlusion is the second most common retinal vascular disorder after diabetic retinopathy. There are many studies reporting the efficacy of intravitreal anti-VEGF injections for macular oedema secondary to retinal vein occlusions. This paper looks at the contrast...
